Top Page
Haleon PLC
(LSE:HLN)
Haleon PLC (HLN) vs. iShares MSCI United Kingdom ETF (EWC)
Haleon PLC Business Overview & Revenue Model
Haleon PLC Earnings Call Summary
Haleon PLC Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.02B | 11.03B | 11.23B | 11.30B | 10.86B | 9.54B |
| Gross Profit | 6.81B | 7.14B | 6.82B | 6.75B | 6.73B | 5.95B |
| EBITDA | 2.79B | 2.83B | 2.68B | 2.67B | 2.68B | 2.21B |
| Net Income | 1.52B | 1.67B | 1.44B | 1.05B | 1.06B | 1.39B |
Balance Sheet | ||||||
| Total Assets | 31.83B | 32.63B | 34.31B | 34.05B | 34.81B | 34.45B |
| Cash, Cash Equivalents and Short-Term Investments | 676.00M | 1.32B | 2.19B | 1.04B | 684.00M | 414.00M |
| Total Debt | 8.54B | 8.61B | 10.10B | 9.46B | 10.44B | 991.00M |
| Total Liabilities | 15.83B | 16.15B | 18.09B | 17.33B | 18.36B | 7.97B |
| Stockholders Equity | 15.94B | 16.43B | 16.17B | 16.61B | 16.33B | 26.36B |
Cash Flow | ||||||
| Free Cash Flow | 931.00M | 2.02B | 1.98B | 1.76B | 1.74B | 1.06B |
| Operating Cash Flow | 1.03B | 2.34B | 2.30B | 2.10B | 2.06B | 1.36B |
| Investing Cash Flow | -76.00M | -580.00M | 528.00M | -134.00M | -8.78B | -33.00M |
| Financing Cash Flow | -2.52B | -2.61B | -1.54B | -1.57B | 6.91B | -1.24B |
Haleon PLC Technical Analysis
Haleon PLC Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | £33.23B | 20.15 | 9.35% | 1.51% | -2.12% | 42.10% | |
65 Neutral | £83.61M | -8.91 | ― | ― | ― | ― | |
63 Neutral | £91.35M | -1.10 | -396.71% | ― | 93.48% | 51.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £28.39M | -11.67 | -51.21% | ― | 61.13% | 33.33% | |
45 Neutral | £728.24M | -9.44 | 227.10% | ― | -0.28% | 22.94% |
Haleon PLC Corporate Events
Haleon plc, the consumer health group behind brands such as Sensodyne, Panadol and Advil, operates globally across oral care, pain relief, vitamins and other everyday health categories, targeting mass-market demand for over-the-counter products. The company leverages its scientific heritage and broad brand portfolio to defend share in key consumer health segments worldwide.
Haleon has published its preliminary full-year 2025 results and proposed a total dividend of 7.1p per share, equivalent to about 38% of adjusted earnings, underscoring strong free cash flow and organic operating profit growth. The board signalled confidence in future performance by indicating it expects to grow the ordinary dividend at least in line with adjusted earnings, a move likely to reassure income-focused investors ahead of a detailed analyst presentation and Q&A on the results.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.20 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon plc has disclosed share transactions by senior executives Adrian Morris, General Counsel, and Jonathan Workman, President Europe, under the company’s Share Reward Plan. Both executives acquired partnership shares and received matching shares in Haleon ordinary stock on 10 February 2026 at a market price of £3.956 per share, with trades executed on the London Stock Exchange.
The reported dealings, though small in volume, underscore ongoing alignment of key management’s interests with shareholders through equity-based incentives. The notification fulfills UK Market Abuse Regulation requirements on transparency of dealings by persons discharging managerial responsibilities, providing investors with visibility into insider participation in Haleon’s share schemes.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon plc has confirmed that as of 31 January 2026 it has 8,952,353,648 issued ordinary shares of £0.01 each, of which 45,557,120 are held in treasury, leaving 8,906,796,528 ordinary shares in issue with voting rights. The company stated that this voting share count should be used by shareholders and other market participants as the reference denominator for assessing disclosure obligations under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules, providing clarity for investors on Haleon’s capital and voting structure.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon plc announced that its Chief Financial Officer, Dawn Allen, has been appointed Chair of the Audit & Risk Committee of ITV plc, effective 5 March 2026. Allen, who has served as a Non-Executive Director and member of ITV’s Audit & Risk Committee since October 2023, will now take on a more prominent governance role at the broadcaster, underscoring the depth of financial and risk-management experience within Haleon’s senior leadership team and potentially strengthening cross-industry ties between consumer health and media.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £430.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon plc has announced a major evolution of its operating model to support its “Win as One” strategy, aiming to boost growth, productivity and organisational agility by mid-2026. The company is creating a new Chief Growth Officer role to consolidate its category, marketing, strategy and commercial excellence activities, and a Chief Transformation Officer to oversee extensive changes in business processes, operating structures and technology. In parallel, Haleon will reorganise its geographic structure into six Operating Units, splitting its current EMEA & LatAm region into separate Latin America, Middle East and Africa, and Europe units, while elevating India Subcontinent to its own unit alongside existing North America and Asia Pacific operations. All Operating Unit presidents, together with the new CGO and CTO, will sit on the executive committee and report to CEO Brian McNamara, reflecting a push toward a simpler, more regionally focused and innovation-driven organisation. The company plans to provide further detail with its full-year results in February 2026, and the changes are expected to sharpen execution in key markets and better leverage Haleon’s global brand portfolio, with implications for how it competes in the global consumer health sector.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon plc has disclosed share transactions by senior executives in line with UK Market Abuse Regulation requirements, confirming that General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers each acquired 34 partnership shares and received 34 matching shares under the company’s Share Reward Plan. The transactions, conducted on 5 January 2026 on the London Stock Exchange, reinforce equity-based alignment between key management and shareholders, signalling continued use of share-based incentives to tie leadership remuneration to the company’s long-term performance.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £440.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon plc has confirmed that as of 31 December 2025 it has 8,952,353,648 ordinary shares in issue, of which 45,745,646 are held in treasury, leaving 8,906,608,002 ordinary shares carrying voting rights. This updated share capital and voting rights figure provides the reference denominator for investors and other stakeholders when assessing whether they must disclose holdings or changes in positions under UK financial disclosure and transparency regulations.
The most recent analyst rating on (GB:HLN) stock is a Buy with a £420.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC has announced significant changes in its board and committee leadership, with Alan Stewart set to become the Senior Independent Director, succeeding Vindi Banga, who will assume the role of Chair effective January 1, 2026. These changes are aligned with the UK Corporate Governance Code 2024, and Vindi Banga’s remuneration as Chair will be £757,103 per annum, as previously disclosed. These leadership adjustments are expected to influence Haleon’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £370.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced the notification and public disclosure of transactions by its managerial staff as per UK Market Abuse Regulation. The transactions involved the acquisition of partnership shares and awarding of matching shares under the company’s Share Reward Plan, impacting the company’s stock management and potentially influencing investor perceptions.
The most recent analyst rating on (GB:HLN) stock is a Hold with a £370.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.
Haleon PLC announced that as of November 30, 2025, it has issued a total of 8,952,353,648 ordinary shares, with 45,882,158 held as treasury shares. This results in 8,906,471,490 shares with voting rights, a figure crucial for shareholders and stakeholders for notification obligations under the FCA’s rules. This announcement is significant for stakeholders as it provides clarity on voting rights and helps in regulatory compliance.
The most recent analyst rating on (GB:HLN) stock is a Sell with a £335.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.